Stock Analysis on Net
Stock Analysis on Net

Cytokinetics Inc. (NASDAQ:CYTK)

This company has been moved to the archive! The financial data has not been updated since November 3, 2023.

Statement of Comprehensive Income 

Comprehensive income is the change in equity (net assets) of a business enterprise during a period from transactions and other events and circumstances from non-owners sources. It includes all changes in equity during a period except those resulting from investments by owners and distributions to owners.

Cytokinetics Inc., consolidated statement of comprehensive income

US$ in thousands

Microsoft Excel
12 months ended: Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018
Net loss (388,955) (215,314) (127,290) (121,692) (106,289)
Unrealized gain (loss) on available-for-sale securities, net (2,721) (1,018) (530) 179 157
Other comprehensive income (loss) (2,721) (1,018) (530) 179 157
Comprehensive loss (391,676) (216,332) (127,820) (121,513) (106,132)

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).

Comprehensive income item Description The company
Net loss The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Cytokinetics Inc. net loss decreased from 2020 to 2021 and from 2021 to 2022.
Comprehensive loss Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Exclude changes in equity resulting from investments by owners and distributions to owners. Cytokinetics Inc. comprehensive loss decreased from 2020 to 2021 and from 2021 to 2022.